Data from an interim analysis of the lumateperone large phase III clinical trial for agitation in subjects with dementia is expected by the end of 2018.
Andrew Satlin, MD
Advertisement
Articles by Andrew Satlin, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial
2
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
3
FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date
4
Building the Foundation for Earlier Alzheimer Disease Diagnosis
5